Quality & Compliance: Regulation of Pharmaceutical Products in Singapore

Posted 01 November 2010 | By

The city/country of Singapore, a member of the Association of Southeast Asian Nations (ASEAN), has a population of 4.9 million characterized by wide ethnic diversity, including Chinese, Malay, Indians and others.1 It is considered a highly developed country with a vibrant economy and a standard of living comparable to that of many Western nations. The significance of Singapore to the pharmaceutical industry is not due as much to its market size as to its strong infrastructure, which has made it a manufacturing center for biomedical products (pharmaceuticals and medical devices). Singapore's national government has invested heavily to attract biomedical companies. It offers business incentives and a protective regulatory environment with strong intellectual property laws to ensure equal treatment of foreign and domestic investors, making it a standard (the Singapore Model) of successful free market economics. Singapore's commitment to the biomedical industry led to the establishment of two state-of-the-art biomedical research parks: the Biopolis, a biomedical research complex, and Tuas Biomedical Park for pharmaceutical, biopharmaceutical and medical-device manufacturing. Pharmaceuticals now account for more than 16% of the country's manufacturing production.2

Categories:

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe